ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
ENDRA Life Sciences Inc. (
NASDAQNDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”).
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update.
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
ENDRA Life Sciences Inc. (
NASDAQNDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego.
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.”
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe.
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update:
ENDRA Life Sciences Announces Reverse Stock Split
ENDRA Life Sciences Inc. (“ENDRA”) (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol “NDRA.” The new CUSIP number for the common stock will be 29273B 401.
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024
ENDRA Life Sciences Inc. (“ENDRA”) (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024.
ENDRA Life Sciences Announces Leadership Changes
ENDRA Life Sciences Inc. (“ENDRA”) (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors. The Company also announced the addition to its senior management team of Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as Chief Financial Officer.
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14
ENDRA Life Sciences Inc. (ENDRA) (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.
ENDRA Provides Update Following In-person Meeting with FDA
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update.
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
ENDRA Life Sciences Inc. (ENDRA) (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of five new patents, including three in Europe and two in China. ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system with its novel thermoacoustic technology.
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
ENDRA Life Sciences Inc. (ENDRA) (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.
ENDRA Life Sciences Installs First TAEUS System in the UK
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health Service (NHS).
New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), welcomes the adoption of the ICD-10 K76.0 code for the diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD). This pivotal update supports recent important advancements in the field of liver disease to underscore the increasing recognition of NAFLD's impact on global health by insurers and healthcare providers alike. ENDRA’s TAEUS system has received a CE mark in the European Union and is the subject of a De Novo request that is pending before the U.S. Food and Drug Administration (FDA).
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology.
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No. 11828727 (the ‘727 patent) titled “Thermoacoustic Probe.”
ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will be participating in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference being held Thursday, December 7, 2023 at the New York Athletic Club in New York City. Management will be holding one-on-one meetings with investors.
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update. Highlights from the third quarter of 2023 and recent weeks include:
ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
ENDRA Life Sciences Inc. (
NASDAQNDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, including one in the U.S. and two in China. ENDRA’s intellectual property (IP) portfolio now includes 70 issued patents worldwide, enhancing the IP protection for the novel TAEUS® system.
